Human Stroke

Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation of its DMT-based compound AP-188 for the potential treatment of stroke.  The research program has now become Algernon's lead drug asset,...

Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and...

Canadian biopharma company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience (AGN Neuro) completed dosing the second cohort of its Phase 1 study on the company’s proprietary IV formulation of DMT, AP-188. It is now moving forward with the final cohort...

Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of a DMT compound. There were no observed safety or tolerability issues, the company stated. Algernon is "breaking new ground in this study in terms of...

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed the first subject in its Phase 1 clinical study of proprietary IV formulation of DMT, AP-188. The trial is being conducted at the Centre...